A common sleep medication appears to do more than just help people fall asleep—it may actually protect the brain from the devastating damage seen in Alzheimer’s disease and related disorders.
New research from Washington University School of Medicine shows that lemborexant, an FDA-approved sleep aid, prevented harmful protein buildup and brain tissue loss in mice genetically engineered to develop Alzheimer’s-like symptoms.
The findings, published May 27 in Nature Neuroscience, suggest a tantalizing possibility: that targeting sleep problems early in neurodegenerative diseases might slow or prevent the brain damage that leads to memory loss and cognitive decline.
More Than Just Better Sleep
What makes this research particularly striking is that lemborexant didn’t just improve sleep—it actively protected brain tissue. Mice receiving the drug showed hippocampal volumes that were 30% to 40% larger than untreated animals, with the hippocampus being crucial for memory formation. These protective effects were specific to lemborexant and weren’t seen with zolpidem, another sleep medication that works through different brain pathways.
“We have known for a long time that sleep loss is a risk factor for Alzheimer’s disease,” said senior author David M. Holtzman, the Barbara Burton and Reuben M. Morriss III Distinguished Professor of Neurology at WashU Medicine. “In this new study, we have shown that lemborexant improves sleep and reduces abnormal tau, which appears to be a main driver of the neurological damage that we see in Alzheimer’s and several related disorders.”
The study focused on tau, a protein that normally helps maintain the structure of brain cells. But when tau becomes abnormally modified—acquiring too many chemical tags called phosphate groups—it can clump together, triggering inflammation and killing neurons. This process occurs not only in Alzheimer’s disease but also in progressive supranuclear palsy, corticobasal syndrome, and certain frontotemporal dementias.
How the Drug Works
Lemborexant belongs to a newer class of sleep medications called dual orexin receptor antagonists. Unlike older sleep aids that target the brain’s calming systems, these drugs work by blocking orexin—small proteins that keep us awake and alert. By shutting down these “wake-promoting” signals, the medication allows natural sleep to occur more easily.
But the researchers discovered something unexpected. The drug’s benefits appeared to go well beyond simply improving sleep quality. When they examined brain tissue from treated mice, they found significantly reduced levels of abnormally phosphorylated tau—the toxic form that causes brain damage. The medication seemed to prevent tau from picking up excess chemical tags in the first place, keeping it in its healthy, functional state.
This protective effect appeared to work through a specific cellular pathway involving cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). When lemborexant blocked orexin receptors, it reduced activity in this pathway, which in turn prevented the excessive phosphorylation that makes tau toxic.
The Sleep-Brain Connection
The relationship between sleep and Alzheimer’s disease has been gaining attention in recent years. Poor sleep quality and sleep disorders often appear years before other symptoms of dementia become apparent. Previous research from Holtzman’s team and others has shown that sleep deprivation can increase levels of both amyloid plaques and tau tangles—the two hallmark proteins of Alzheimer’s disease.
What remained unclear was whether improving sleep could actually prevent or reverse this damage. The new study suggests it might, at least in the case of tau-related pathology.
The researchers used mice genetically modified to develop tau accumulation and tested lemborexant over two months. Animals receiving the drug not only slept better but also showed reduced brain inflammation, preserved synaptic connections between neurons, and maintained larger brain volumes in critical memory regions.
A Puzzling Gender Difference
One of the study’s most intriguing findings was that the protective effects appeared only in male mice. Female animals showed improved sleep but no reduction in brain damage, a pattern that surprised the researchers and highlights the complex ways that sex can influence neurodegeneration.
Holtzman speculated that this difference might relate to the observation that female mice in this particular model develop less severe tau-related damage to begin with. “With less damage to begin with, potential beneficial effects of the drug could have been smaller and more difficult to detect,” he explained.
This sex difference underscores the importance of studying both males and females in neurodegenerative disease research and suggests that treatments might need to be tailored differently for men and women.
Clinical Implications
While these results are promising, significant questions remain before lemborexant could be recommended for preventing Alzheimer’s disease in humans. The study was conducted in mice with genetic predispositions to tau accumulation, and it’s unclear whether similar benefits would occur in people with age-related neurodegeneration.
Additionally, the research involved giving the drug to mice before extensive brain damage had occurred. Whether lemborexant could help people who already have significant tau pathology remains to be tested.
However, the findings add to growing evidence that sleep interventions might play a role in comprehensive approaches to preventing neurodegenerative diseases. Current Alzheimer’s treatments primarily target amyloid plaques and provide only modest benefits in slowing cognitive decline.
“The antibodies to amyloid that we now use to treat patients with early, mild Alzheimer’s dementia are helpful, but they don’t slow the disease down as much as we would like,” Holtzman noted. “We need ways to reduce the abnormal tau buildup and its accompanying inflammation, and this type of sleep aid is worth looking at further.”
Looking Forward
The research team is planning additional studies to better understand the mechanisms behind lemborexant’s protective effects and to explore whether combining different therapeutic approaches might be more effective than any single treatment alone.
Key findings from the study include:
- Lemborexant reduced abnormal tau phosphorylation by approximately 50% in treated male mice
- Brain tissue volumes in memory-critical regions were 30-40% larger in treated animals
- The drug decreased inflammation markers and preserved synaptic connections
- Benefits required blocking orexin receptors specifically, not just improving sleep
- Effects were limited to male mice in this particular disease model
The study represents a collaboration between Washington University researchers and Eisai, the pharmaceutical company that developed lemborexant. While the drug is already approved for treating insomnia, these findings suggest it might have broader therapeutic potential for neurodegenerative diseases characterized by tau pathology.
For people concerned about Alzheimer’s risk, the research reinforces the importance of maintaining healthy sleep patterns, though it’s far too early to recommend lemborexant specifically for neurodegeneration prevention. As our understanding of the sleep-brain connection continues to evolve, it’s becoming increasingly clear that a good night’s rest might be one of our most powerful tools for maintaining brain health throughout life.
ScienceBlog.com has no paywalls, no sponsored content, and no agenda beyond getting the science right. Every story here is written to inform, not to impress an advertiser or push a point of view.
Good science journalism takes time — reading the papers, checking the claims, finding researchers who can put findings in context. We do that work because we think it matters.
If you find this site useful, consider supporting it with a donation. Even a few dollars a month helps keep the coverage independent and free for everyone.